Data / Drug companies / Valganciclovir hydrochloride
Valganciclovir hydrochloride: 11 companies and 14 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Valganciclovir hydrochloride is listed in the FDA National Drug Code Directory by 11 companies, with 14 products in commercial distribution. 13 of the products (92.9%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are powder, for solution; tablet; tablet, film coated, and the newest product started marketing on March 1, 2026.
The request: Get every company that lists valganciclovir hydrochloride in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 11
- Products
- 14
- Generic (ANDA) products
- 13 (92.9%)
- Application numbers
- 8
- Routes
- Oral
- Brand names
- Valganciclovir, Valganciclovir, Valcyte
- openFDA record search
- api.fda.gov
Companies that list valganciclovir hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| AvKARE | 2 | powder, for solution; tablet, film coated | Generic drugs (ANDA) | December 21, 2023 |
| NorthStar RxLLC | 2 | powder, for solution; tablet | Generic drugs (ANDA) | March 1, 2026 |
| Strides Pharma Science Limited | 2 | tablet, film coated | Generic drugs (ANDA) | June 16, 2025 |
| Actavis Pharma, Inc. | 1 | powder, for solution | Generic drugs (ANDA) | August 26, 2016 |
| Ajanta Pharma USA Inc. | 1 | powder, for solution | Generic drugs (ANDA) | January 13, 2020 |
| American Health Packaging | 1 | powder, for solution | Generic drugs (ANDA) | August 20, 2023 |
| Aurobindo Pharma Limited | 1 | tablet | Generic drugs (ANDA) | March 31, 2016 |
| Camber Pharmaceuticals, Inc. | 1 | powder, for solution | Generic drugs (ANDA) | October 4, 2022 |
| Dr. Reddy's Laboratories Inc. | 1 | tablet | Generic drugs (ANDA) | December 12, 2017 |
| H2-Pharma, LLC | 1 | powder, for solution | New drug applications (NDA) | August 28, 2009 |
| Novadoz Pharmaceuticals LLC | 1 | for solution | Generic drugs (ANDA) | February 17, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder, for solution | 7 | 50% |
| Tablet | 3 | 21.4% |
| Tablet, film coated | 3 | 21.4% |
| For solution | 1 | 7.1% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 13 | 92.9% |
| New drug applications (NDA) | 1 | 7.1% |
Pharmacologic classes
| Class | Products |
|---|---|
| Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor | 14 |
| Nucleoside Analog Antiviral | 14 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.